Editas Medicine, Inc. (EDIT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US28106W1036
Editas Medicine, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 40.52 m USD |
| Operating income | -160.01 m USD |
| EBIT | -157.93 m USD |
| Net income | -160.06 m USD |
| Diluted EPS – continuing operations | -1.80 USD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
More stocks
- Guangdong Jinming Machinery Co Ltd (300281.SZ)
- ABC arbitrage SA (ABCA.PA)
- Ventura Offshore Holding Ltd. (VTURA.OL)
- Forward Industries, Inc. (FWDI)
- Jiusheng Electric Co. LTD (301082.SZ)
- Hanil Cement Co Ltd (003300.KS)
- Borussia Dortmund GmbH & Co KGaA (BVB.DE)
- TrueBlue, Inc. (TBI)
- Shandong Xinjufeng Technology Packaging Co. Ltd. A (301296.SZ)
- Indaptus Therapeutics, Inc. (INDP)
- Investar Holding Corp (ISTR)
- YC Inox Co Ltd (2034.TW)
Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.